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Abstract 
 
Aim: Increasing use of SSRIs in Scotland, coupled with safety concerns with some SSRIs, and the 
increasing availability of generic SSRIs, have resulted in multiple initiatives to improve the quality and 
efficiency of prescribing. Our aim is to assess their influence to provide future direction. Materials & 
methods: PCA database to document utilisation and expenditure on SSRIs between 2001 to 2017 
and document initiatives. Results: Multiple interventions over the years increased INN prescribing up 
to 99.9% lowering overall costs. This coupled with initiatives to limit escitalopram prescribing due to 
concerns with its value resulted in a 73.7% reduction in SSRI expenditure between 2001 and 2017 
despite a 2.34-fold increase in utilisation. Safety warnings resulted in a significant reduction in the 
prescribing of paroxetine, citalopram and escitalopram alongside a significant increase in sertraline 
Conclusion: Multiple initiatives have increased the quality and efficiency of SSRI prescribing in 
Scotland providing direction to others. 
 
1. Introduction 
 
Across countries, there has been considerable growth in the use of medicines. In part, this has been 
driven by aging populations, an increase in primary prevention strategies, as well as single disease 
model guidelines and policies [1,2]. We have also seen the continual launch of new high-priced 
medicines [2,3]. These factors combined are adding to resource pressures within countries resulting 
in models and initiatives to address this [2-5]. Scotland is no exception, and during the last 20 years 
or more there have been multiple initiatives to enhance the quality and efficiency of prescribing to help 
improve patient outcomes within finite resources providing direction to other countries.  
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Initiatives include encouraging high rates of international non-proprietary name (INN) prescribing with 
generics typically seen as similar to the originator in all but a minority of situations [6-8]. This is 
important as there are still concerns with generics across a number of countries [9-11]. Savings once 
generics become available in Scotland are enhanced by their reduced costs, which can be as low as 
3% of pre-patent loss originator prices [12,13]. INN prescribing is important in Scotland as 
pharmacists are not currently allowed to switch an originator or branded product to a generic if the 
physician prescribes the originator or branded product [7,14,15]. Alongside this, there have also been 
initiatives to increase the prescribing of multiple sourced products (generics) versus on-patent 
products in a class or related class where this does not compromise care to further save on costs. 
Classes include the proton pump inhibitors (PPIs), renin-angiotensin receptor blockers and statins 
[12,13,15].  
 
Concomitant with this, there have also been multiple measures in Scotland to improve the quality of 
prescribing. These include encouraging physicians to prescribe higher doses of statins to improve 
long term outcomes as well as initiatives to reduce the prescribing of lipid lowering agents where 
there have been concerns with their effectiveness [12,15]. There have also been national and regional 
initiatives in Scotland to reduce the doses of PPIs prescribed, as well as encourage regular 
monitoring of patients on long-term PPIs, due to concerns with the consequences of their long term 
use [16-19].    
 
Depression and other mental health conditions such as anxiety disorders are prevalent in Scotland 
with 11.3% of the adult population in 2010 to 2011 prescribed antidepressants [20]. These high rates 
of prescribing are possibly influenced by Westernised societies’ expectations of happiness, and 
consequential medicalisation of unhappiness [21,22], as well as expansion of the indications for 
antidepressants. The selective serotonin re-uptake inhibitors (SSRIs) are the most frequently 
prescribed antidepressants in Scotland, accounting for over 50% of all antidepressants prescribed in 
recent years [20,23,24].  However, unlike the PPIs, renin-angiotensin blockers and statins, the 
situation with antidepressants is more challenging as they are not readily interchangeable, which 
limits the potential for therapeutic switching within a class [12,13,15,25,26]. This is because 
antidepressants such as the SSRIs exhibit subtle differences, which can affect both their efficacy and 
side-effects [27-29]. Having said this, there have been activities among the Health Boards (Regions) 
in Scotland to limit the prescribing of escitalopram versus other SSRIs, including fluoxetine and 
citalopram, where there have been considerable differences in costs but limited differences in patient 
outcomes [ 17, 30-32]. Health Board activities included prescribing targets for escitalopram [33]. They 
also include switching suitable patients prescribed escitalopram prior to citalopram to now being 
prescribed citalopram (C Johnson personal communication). Encouragingly, 90% of patients 
remained on citalopram after the switch at a three-month review. Such activities are important from a 
health policy perspective as they help to conserve resources without compromising care. 
 
We have also seen initiatives in other countries to influence the prescribing of antidepressants where 
there have been concerns. This includes instigating prescribing restrictions for duloxetine in the 
management of patients with depression in Sweden due to concerns with its effectiveness and costs 
versus other antidepressants [ 34], as well as education and other activities to limit the prescribing of 
vortioxetine again due to concerns with its cost-effectiveness [35,36]. Such activities are likely to 
continue. 
 
We are also aware that there have be concerns with the increased risk of suicides with paroxetine as 
well as other SSRIs since the early 2000s [37-42]. In addition, paroxetine is associated with a higher 
incidence of discontinuation symptoms versus other SSRIs, which necessitates a longer period of 
dose reduction [43]. There have also been concerns with potential QTc interval prolongation and 
Torsade de Pointes with citalopram and escitalopram from 2011 onwards [44], although the latter may 
be infrequently reported [45]. The concerns with possible QTc interval prolongation with citalopram 
and escitalopram resulted in the MHRA in the UK and Health Boards in Scotland providing guidance 
on their use [46-69]. This included recommending alternative SSRIs for new patients, as well as for 
patients where there were concerns with citalopram and escitalopram. This included sertraline with 
evidence of potential improved effectiveness and safety versus other SSRIs [48,50,51]. We are also 
aware that Health Boards in Scotland have also assessed factors associated with higher doses of 
SSRIs being prescribed [20,52]. Available evidence does not support the routine prescribing of higher 
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doses of SSRIs for the treatment of depression as this is known to increase anxiety, agitation and 
insomnia [53].  
 
As a result of multiple activities in Scotland, rates of INN prescribing for the SSRIs were as high as 
98% - 99% of their total utilisation in 2007 [13]. This coupled with initiatives to limit the prescribing of 
escitalopram versus citalopram resulted in expenditure on the SSRIs falling in Scotland by 59% 
between 2001 and 2007 despite a 2.37 fold increase in their utilisation [13]. This compares with 
appreciably increased expenditure for the SSRIs in Ireland (72% higher) and Portugal (93% higher) in 
2008 and 2007 versus 2001 respectively where there were limited measures in both these countries 
to encourage the prescribing of lower costs multiple sourced SSRIs (generics) versus originators as 
well as on-patent escitalopram [13,54]. Such activities are important among high income countries 
with universal healthcare systems due to the continuous growth in the prescribing of medicines for 
patients with non-communicable diseases with ageing populations resulting in constant financial 
pressures, which is enhanced by the continual launch of new premium priced medicines to address 
areas of unmet need [2,4,55,56]. Obtaining low prices for good quality generics, and promoting their 
use, is also very important in low and middle income countries where access to medicines can be an 
issue with high patient co-payment levels [57,58]. Without such considerations, illness among family 
members can be potentially catastrophic for them [58,59]. Currently, fluoxetine is included in the WHO 
list of essential medicines [60]. 
 
Consequently, the objectives of this paper are multiple. Firstly, to assess the influence of the various 
multiple measures in Scotland on the overall volume and expenditure on the SSRIs in recent years, 
building on the earlier analysis [13]. Secondly, assess the extent of INN prescribing as well as the 
extent of price reductions for SSRIs following generic availability to help fund increased prescribing 
volumes without increasing costs, again building on the earlier analysis [13]. Thirdly, assess the 
extent of changes in the utilisation of citalopram, escitalopram, paroxetine and sertraline in recent 
years as a result of multiple initiatives and safety warnings. The findings will help guide future 
activities in Scotland as well as other countries, as all countries are looking to improve the quality and 
efficiency of their prescribing due to continuing pressures on resources.  
 
We are also aware that there is a growing requirement for research evidence to guide future activities 
and initiatives to improve the selection, affordability, and rationality of prescribing of medicines for 
patients with mental disorders, which can be considered as public health psychopharmacology [61]. 
We hope our findings helps to start addressing this deficit. 
 
2. Methodology 
2.1 Utilisation and expenditure data 
We used the prescription costs analysis (PCA) data in Scotland to analyse utilisation and expenditure 
data in ambulatory care [62]. PCA data is compiled by the Information Services Division (ISD) of NHS 
Scotland, which is an open source data set collecting data on the utilization and expenditure of 
medicines dispensed in community pharmacies in Scotland. The NHS in Scotland is a tax payer 
funded free at point of access health service, with currently no co-payment for medicines. 
 
Information extracted from the PCA for each SSRI (N06AB – [63]) between 2001 and 2017 included: 
their generic name, commercial name(s), formulation(s), drug strength(s), number of dispensed units, 
cost per unit and total expenditure. The costs are in Great Britain pounds (GB£s) and include the 
gross ingredient costs (GIC) and cost per item for all SSRIs medicines dispensed during this period. 
No adjustment for inflation for prices was made, which is in line with previous studies, due typically to 
the rapid reduction in prices in the UK once originators become available as generics [12,13,64].  
 
Whilst we are aware NHS Scotland routinely uses defined daily doses (DDDs) when presenting and 
discussing utilization data in line with international guidance [23,63,65] especially when different 
strengths are available such as citalopram (10mg, 20mg, 40mg) and sertraline (50mg, 100mg). 
However, we used items dispensed as we wanted to track this to reflect individual prescriptions, 
especially following changes in prescribing guidance, similar to the situation with lipid lowering agents 
and PPIs [15,19]. In the case of patients with chronic diseases such as depression, a prescription in 
terms of ‘items dispensed’ is usually for 28 or 56 days. However, as previously identified, there can be 
a tendency in recent years for physicians to increase the length of a prescription to help with their 
growing workloads [15]. 
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2.2 Demand-side measures 
As before, ongoing activities within the Health Boards and NHS Scotland to encourage INN 
prescribing as well as selected SSRIs have been collated using the 4E methodology: Education, 
Engineering, Economics and Enforcement [12,13.15,66]. Education refers to initiatives such as 
prescribing guidance and guidelines; engineering refers to organizational or managerial interventions 
such as prescribing targets; economics to financial incentives such as prescribing incentive schemes; 
and enforcement refers to regulations from health authorities [13,15,66]. However, the latter is rare in 
Scotland with no actual enforcement of regulations as seen for instance in Sweden with compulsory 
generic substitution and prescribing restrictions for statins in Finland and Norway following generic 
simvastatin [67-69]. 
 
We did not typically undertake any time-series analyses as multiple interventions inter-linked activities 
were undertaken at different times both nationally and regionally between 2001 and 2017. However, 
we did undertake such a time-series analysis comparing the changes in the items dispensed for 
citalopram and escitalopram before and after the warnings regarding possible QTc interval 
prolongation and any subsequent influence on the utilisation of recommended SSRIs such as 
sertraline [70]. A p value > 0.05 was seen as significant.  
 
3. Results 
3.1 Generic availability of SSRIs 
 
Table 1 contains details of the year of patent expiry of the different SSRIs in Scotland. 
 
Table 1 - SSRIs and their patent expiration date in Scotland from 2001 to 2017 
 
Generic name Commercial name 
(Originator) 
ATC Code Year of patent 
expiration 
Fluvoxamine Faverin® N06AB08 Prior to 2000 
Fluoxetine Prozac® N06AB03 2000 
Paroxetine  Seroxat® N06AB05 Prior to 2000 
Citalopram Cipromil® N06AB04 2002 
Sertraline Lustrall® N06AB06 2005 
Escitalopram  Cipralext® N06AB10 2014 
 
3.2 Influence of multiple measures 
A number of demand-side measures have been introduced nationally and regionally in Scotland in 
recent years to enhance INN prescribing as well as influence the prescribing of different SSRIs due 
either to concerns with their safety or value. These are summarised in Table 2. 
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Table 2 - Summary of principal demand-side measures introduced in Scotland between 2001 and 
2017 that influenced SSRI utilization patterns [13,17,30,31,33,40,46,48,49,51,52,71-76]  
 
Measure Year National or 
Regional 
Initiative 
Education 
2001 to 2017 National and 
Regional 
 Physicians typically trained in medical school to 
prescribe by INN name with subsequent activities in 
GP practices coupled with IT systems to enhance 
INN prescribing 
2003 National  National warning regarding paroxetine in children 
2003 Regional 
(Lothian) 
 Lothian highlighting the extent of savings from the 
prescribing of generic paroxetine vs originator  
2006 Regional 
(GGC) 
 Fluoxetine and citalopram recommended SSRIs on 
the formulary list 
2008 
onwards 
Regional 
(GGC) 
 Educating GPs to regularly review patients on long-
term antidepressants (doses prescribed, 
effectiveness, treatment duration, guideline 
improvements and costs)  
2009 Regional 
(GGC) 
 Fluoxetine and citalopram recommended SSRIs on 
the formulary list 
2010 Regional 
(GGC) 
 Sertraline added to the recommended formulary list 
of SSRIs  
2009/10 to 
2015 
Regional 
(GGC) 
 Review of patients receiving the same 
antidepressant for ≥2 years conducted among 180 
GP practices involving > 8000 patients, the majority 
of whom receive SSRIs 
2011 National  MHRA warning on QT interval prolongation with 
citalopram and escitalopram 
2012 and 
2015 
Regional 
(GGC) 
 Escitalopram and citalopram at high risk of QT 
prolongation  
2012 Regional 
(Tayside) 
 Warnings of QT interval prolongation with 
citalopram and escitalopram 
2013 Regional 
(Lothian) 
 Guidance on potential risks associated with the 
prolongation of QTc interval with different 
psychotropic medicines 
2017 NHS 
Grampian 
 Fluoxetine and sertraline recommended SSRIs with 
sertraline recommended in patients with 
cardiovascular disease (caution with citalopram) 
Engineering 
    
2002 National  Audit Scotland benchmarking DDDs of non-
fluoxetine SSRIs and the extent of INN prescribing 
across Scotland 
2007 National  Health improvement, Efficiency, Governance, 
Access to services and Treatment (HEAT) targets.  
NHS Boards to reduce the annual rate of increase 
of defined daily dose per capita of antidepressants 
to zero by 2009/10, and put in place the required 
support framework to achieve a 10% reduction in 
future years 
2007/ 2008 Regional 
(Lothian) 
 Total number of prescribed items of escitalopram ≤ 
10% of all SSRIs (also linked with financial 
incentive schemes – Economics) 
2008/09 to 
2012/13 
Regional 
(GGC) 
 Fluoxetine & citalopram as a % of all SSRIs, 
duloxetine, mirtazapine, reboxetine and venlafaxine 
items ≥65% (or an absolute increase of 5%) items 
and linked with prescribing financial incentives 
(Economics) 
2009/10 Regional 
(GGC) 
 Escitalopram prescribing <5% of all SSRIs items 
and linked to prescribing financial incentives 
(Economics) 
 Fluoxetine 60mg capsules to 3x20mg capsules 
(GB£39/ patient as opposed to GB£360/patient) 
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and linked to prescribing financial incentives 
(Economics) 
2011/2012 Regional 
(GGC) 
 Citalopram and escitalopram QTc prolongation 
reviews of patients 
Economics 
(in addition 
to the above) 
Ongoing National/ 
Regional 
 Practice incentive schemes for reaching agreed 
prescribing targets 
Enforcement 
(although no 
actual 
enforcement 
in Scotland 
2002/ 2006 National  Escitalopram initial rejected for use in NHS 
Scotland in 2002; however, accepted for use in 
2006 
 
3.3 Total utilisation and expenditure 
There was a steady increase in the number of total SSRI items dispensed between 2001 and 2017 
(Figure 1).  
 
Figure 1 – SSRI utilisation (items dispensed) in Scotland 2001 to 2017 
 
 
NB: The solid lines indicate the time points where generics became available; [A] fluvoxamine, fluoxetine and 
paroxetine were already available by 2001; [B] generic citalopram; [C] generic sertraline; [D] generic escitalopram 
[D] 
 
1.393 million items were dispensed in 2001 with a cost of GB£28.937 million, rising to 3.258 million 
items dispensed in 2017 at a cost of GB£7.613 million. This represents a 2.34-fold increase in SSRI 
utilisation during this period but a 73.7% reduction in expenditure.  
 
The increase in SSRI utilisation during this period has been predominantly driven by increasing 
utilisation of citalopram, initially rising from 19.8% of total SSRI items dispensed in 2001 (276 
thousand items) to 51.3% in 2012 (1.352 million items) before falling to 35.6% in 2017 following 
concerns with QT prolongation (Table 2). During this period, sertraline utilisation rose appreciably 
from 10.32% of total SSRI utilisation in 2011 to 31.8% in 2017. Concurrent with this, fluoxetine 
utilisation fell gradually from 33.2% of total SSRI items dispensed in 2001 to 26.3% in 2017 (Figure 1). 
The utilisation of paroxetine fell steadily throughout the study period from 32.7% of total utilisation in 
2001 to 4.1% in 2017 following safety and other concerns, although these were not exclusively 
attributable to paroxetine. Overall during the study period, the number of items of paroxetine 
dispensed fell by 70.8%. There was low utilisation of escitalopram throughout the study period, 
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reaching a maximum of 6.99% of total items dispensed in 2007 before falling to 2.1% of total items 
dispensed in 2017 (Figure 1).  
 
Figure 2 depicts a fall in total expenditure in recent years as more SSRIs lost their patent (Table 1).  
 
Figure 2 – Total expenditure on SSRIs in Scotland between 2001 and 2017 
 
  
 
This fall in SSRI expenditure was driven by a reduction in expenditure per item of the various SSRIs 
especially after generic availability (Figure 3), with Table 3 depicting the price reductions over time for 
each SSRI that had lost its patent during the study period, i.e. after 2001 (Table 1). Typically, the 
generic versions of SSRIs were dispensed once available with high rates of INN prescribing (Table 4). 
 
Figure 3 – Cost per item dispensed for the different SSRIs and total 2001 to 2017 
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Table 3 – Price reduction in expenditure/ item dispensed for the various SSRIs in 2017 that had lost 
their patent after 2001 versus their prices just before patent loss 
 
SSRI % reduction in 2017 
Citalopram 91.6 
Sertraline 91.8 
Escitalopram 90.4 
 
Table 4 – Rates of INN utilisation (items dispensed) of regularly prescribed SSRIs during the study 
period 
 
SSRI % INN (items dispensed) 
Paroxetine 91.4% - 98.1% 
Fluoxetine 98.7% - 99.7% 
Citalopram 99.5% - 99.9% 
Sertraline 98.5% - 99.7% 
 
3.3 Differences in SSRI utilisation patterns before and after concerns with QT prolongation 
 
Figure 4 depicts the changes in the utilisation (items dispensed) of citalopram, escitalopram and 
sertraline before and after concerns with potential QT prolongation with citalopram and escitalopram 
(Table 2), i.e. 2001 to 2011 and after 2012 
 
Figure 4 – Extent of utilisation of citalopram, escitalopram and sertraline in Scotland 2001 to 2017 
 
 
 
After the concerns with potential QT prolongation associated with citalopram and escitalopram use in 
2012, there was a significant decreasing trend in citalopram and escitalopram use of 142,951 
items/year (p<0.001) whilst the trend for prescribing of sertraline increased significantly by 141.016 
items/year (p<0.001). 
 
Discussion 
 
There has been an appreciable growth in SSRI items dispensed during the study period rising 2.34-
fold (Figure 1). This may well be due to a widening of the indications for SSRIs to include anxiety as 
well as increasing diagnosis of depression as the diagnosis of depression and its management has 
now always been routinely recorded and coded as part of general practice contractual obligations 
0
2
4
6
8
10
12
14
16
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
N
u
m
b
er
 o
f 
it
em
s 
d
is
p
en
se
d
 (
1
0
5
)
Year
Citalopram + escitalopram  combined Sertraline
10 
 
[20,77], and depression has been under-detected and under-treated. This may lead to under reporting 
of this common illness even when patients are now more likely to seek help for their emotional 
distress [78]. The recent mental health and wellbeing survey suggests that one in six adults in 
England have a common mental disorder, with more people now seeking treatment [79]. The survey 
data from England indicates there has been an increase in the proportion of people with clinical 
anxiety or depression disorders accessing mental health treatments, up from 24% in 2007 to 39% in 
2014 [79]. There is no reason why Scotland should be any different from the findings in England. 
Patients are also receiving longer treatment [80]. Overall, we believe this growth in SSRI prescribing 
in Scotland in recent years (Figure 1) has been due to a combination of factors. These include SSRIs 
becoming available as low cost generics (Table 1, Figure 3), and adopted as first line agents for the 
treatment of depression combined with additional prescribing targets (Table 2); an increase in 
prevalence rates and patients accessing mental health services; increasing long-term use; a lack of a 
regular proactive review of patients when they are stable and not in crisis; and the routine use of 
higher SSRI doses, which is contrary to current guidelines and evidence [17,30,43,52,77-82]. 
 
The potential associated costs with this growth in SSRI utilisation have been offset by a considerable 
reduction in the cost/ item for the various SSRIs apart from fluvoxamine (Figure 3). The price 
reductions seen for the various SSRIs over time (Table 3) mirror those for the lipid lowering agents, 
losartan, PPIs and risperidone [15,19,83,84]. This coupled with high INN (Table 4) prescribing rates 
has resulted in an appreciable reduction in SSRI expenditure (73.7% reduction in 2017 versus 2001) 
to GB£7.613 million in 2017 (Figure 2). This is similar to the situation with lipid lowering agents and 
PPIs in Scotland [15,19] providing guidance to other countries struggling with resource pressures. 
 
The high rate of INN prescribing for the SSRIs in Scotland as a result of multiple activities (Table 2) is 
also similar to the situation seen with generic PPIs, statins, renin-angiotensin drugs and anti-
psychotics in Scotland [13,15,19,84,85]. This is encouraging and suggests no problems with the 
effectiveness and safety of generic SSRIs over many years. This is important for countries where 
there is still considerable prescribing of originator antidepressants despite the availability of good 
quality generics. This is not in the best interest of any key stakeholder group long term with potential 
resources being wasted, which could have been used to fund improved care in other situations 
including new medicines in patients with unmet need.   
 
The reduction and then rise in the cost/ item for fluvoxamine (Figure 3) may be a reflection of its 
limited use (Figure 1); consequently, limited competition and need to reduce prices. This is seen in 
other situations across Europe [86]. However, this situation has made limited difference to the overall 
expenditure on SSRIs in Scotland with typically expenditure on fluvoxamine ranging from 0.21 to 
0.85% of total SSRI expenditure during the study period.  
 
The low utilisation of escitalopram in 2007 in Scotland at 6.99% of total SSRIs dispensed (7.0% DDD 
basis) and 6.51% in 2008 compares favourably with 17.3% in Portugal (DDD basis) in 2007 and 
30.8% in Ireland in 2008 [13] following multiple initiatives (Table 2). This is the only example of 
generic availability (citalopram) influencing the prescribing of patented SSRIs (escitalopram). As 
mentioned, GPs certainly in Glasgow were encouraged to switch suitable patients who were 
prescribed escitalopram prior to citalopram to citalopram. This was seen as an effective measure to 
conserve resources without compromising care with, as mentioned, typically 90% of patients 
remaining on citalopram at the three-month review. Otherwise, there was no routine switching of 
SSRIs between patients. This was unlike the situation with the PPIs and statins in Scotland with no 
perceived differences in effectiveness between them [15,19]. Unlike the PPIs and statins, there were 
no national indicators encouraging the prescribing of particular SSRIs, although there were regional 
targets discouraging the prescribing of escitalopram (Table 2) [15,19,24]. This recognises the fact that 
patients being treated for depression are considered more vulnerable and therefore their medication 
once seen as effective and tolerated is typically not changed. In addition, antidepressants certainly 
initially are prescribed as courses rather than life-long chronic treatment; consequently, a change to a 
different SSRI was generally through trying to influence the initial prescription rather than switching 
patients once prescribed a particular SSRI (Table 2). The situation  with escitalopram was different 
(Table 2) as there was perceived limited clinical differences with citalopram; however, considerable 
differences in costs once generic citalopram became available (Figure 3).   
 
The utilisation patterns for paroxetine (Figure 1) were in line with expectations following the safety 
warnings; however, these were not exclusive to paroxetine although paroxetine was singled out 
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initially [37,38,41]. In addition, concerns with the need for lengthier dose reductions following the 
decision to stop prescribing [43]. 
 
The significant reduction in the utilisation citalopram and escitalopram, coupled with significantly 
increased use of sertraline in recent years, is also encouraging following safety warnings (Table 2, 
Figure 4).  This further illustrates the favourable influence of both national and regional initiatives on 
effecting physician prescribing habits, which is not always the case [87-89]. As a result, again 
providing guidance to other countries. 
 
Limitations 
We are aware of a number of limitations with this study. This includes the fact that we were only able 
to analyse prescriptions dispensed and not their indication. However, two large studies in one Scottish 
Health Board area indicating that 87% of antidepressants were prescribed for depression, and less 
than 3% were prescribed for non-licensed indications [20,77]. We could also not analyse the strength 
of doses prescribed to ascertain whether there were any change in the doses of SSRIs prescribed 
although two regional Scottish studies indicate that higher SSRIs doses are possibly being prescribed 
more commonly [20,78]. We are aware that there are multiple factors which are associated with 
prescribing of higher SSRI doses including which anxiety disorders are being treated. For depression, 
which general practice a patient attends, if they are prescribed an SSRI for two years or more, and if 
they are co-prescribed benzodiazepines and/or z-hypnotics for more than 8 weeks [20]. We also did 
not analyse utilisation in terms of DDDs, which would have been more sensitive to changes in the 
doses of SSRIs prescribed; however, such studies have been undertaken. We could also not assess 
patient outcomes with the changes in SSRI prescribing patterns. Finally, from a safety perspective 
assessing the impact of the MHRA warning on the incidence of QTc prolongation and sudden cardiac 
death is very challenging as QT prolongation as a cause of death cannot be confirmed at autopsy. 
From a efficacy and wellness perspective, there are challenges with routinely collecting for patient-
level outcome data in ambulatory care for common mental health problems; consequently, limiting a 
national assessment of the impact of SSRI prescribing. Despite these limitations, we believe our 
findings are robust and provide guidance for the future.  
 
Conclusion 
 
The considerable reduction in the cost of SSRIs over the years once generics became available has 
resulted in lower costs despite an appreciable increase in SSRI utilisation. This is to the benefit of all 
key stakeholders since the savings can be used in other disease areas such as funding new 
medicines that address current unmet need within a resource constrained environment. 
 
Overall, the loss of patents has not influenced SSRI prescribing patterns apart from escitalopram. 
This is unlike the situation seen with the PPIs and lipid lowering medicines, and reflects the 
differences in the effectiveness and safety of the different SSRIs. 
 
The changes in the prescribing patterns of paroxetine, citalopram and escitalopram are encouraging 
and shows healthcare professionals in Scotland act quickly on safety and other warnings, providing 
an example to other countries.  
 
Finally, we believe analyses such as this as part of public health psychopharmacology are justified 
and provide practical research findings to guide future care. Consequently, we see this discipline 
growing in the future. 
 
Summary points 
 There is increasing use of antidepressants including SSRIs in Scotland in recent years with 
expanding of indications, greater awareness and medicalisation of depression, and greater 
number of patients accessing treatment for their depression  
 There have also been safety concerns with some SSRIs including initially paroxetine and 
subsequently citalopram and escitalopram 
 The increasing availability of generic SSRIs. the need to conserve costs including limiting 
prescribing of patented escitalopram, and safety concerns has resulted in multiple initiatives in 
Scotland in recent years 
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 High INN prescribing (up to 99.9%) and generics up to 92% below originator prices, coupled with 
initiatives to limit escitalopram prescribing, resulted in a 73.7% reduction in SSRI expenditure 
between 2001 and 2017 despite a 2.34-fold increase in utilisation 
 The safety warnings resulted in a significant reduction in the prescribing of paroxetine, citalopram 
and escitalopram coupled with a significant increase in the prescribing of sertraline 
 Overall the multiple initiatives have increased the quality and efficiency of prescribing 
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